Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG – RAPID Trial): A structured summary of a study protocol for a randomised controlled trial
입원한 COVID-19의 응고병증: COVID-19 유행병에 대한 신속한 대응으로서 치료용 항응고제 대 표준 치료의 실용적인 무작위 통제 시험(RAPID COVID COAG – RAPID 실험): 무작위 통제 실험을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] 1:1
absence
acutely ill hospitalized medical patients
Admission
age
allergy
allocation concealment
allocation sequence
Alpha
America
and protocol
Anticoagulant
anticoagulation
antiplatelet
antithrombotic therapy
apixaban
arterial
bleeding
bleeding risk
Blinding
block sizes
blood cell
Brazil
can not
Canada
Care
Chain Reaction
changed
choice
clinical trial
clinically
clinician
Coagulation
Coagulopathy
Committee
complex
Composite
computer-generated
contraindication
control group
Controlled
COVID
COVID-19
Critical
Critical illness
cryoprecipitate
D-dimer
D-dimer value
Dabigatran
dalteparin
Date
death
defined
dependent on
detect
determine
diagnosis of SARS-CoV-2
diagnostic
Diagnostic imaging
discretion
disorder
dissemination
dose
dual
edoxaban
electrocardiogram
element
elevated
emergency room
enoxaparin
Enrollment
evaluated
exclusion criteria
expected
experimental group
fibrinogen
fondaparinux
frozen plasma
Health Organization
hemoglobin
heparin
heparin-induced thrombocytopenia
High dose
high risk
hospital
Hospital admission
hospitalised
Hospitalized
hospitalized patient
hospitalized patients
ICU
ICU admission
include
inclusion criteria
indicated
individual
inflammatory biomarkers
Informed consent
INR
intensive care
intensive care unit
Interactive Web Response System
intermediate dose
Invasive mechanical ventilation
involved
Ireland
isothermal amplification
judgement
limit
LMWH
Local
low molecular weight
low molecular weight heparin
Major
major bleeding
mechanical ventilation
Non-invasive
non-invasive positive pressure ventilation
nucleic acid
number
objective
occur
Open-label
open-label trial
outcome
oxygen
oxygen saturation
participant
Patient
patients
Phase 3
plasma
Platelet
Platelet count
Platelets
polymerase chain
polymerase chain reaction
positive pressure
positive pressure ventilation
power
Pregnancy
pressure ventilation
protocol
random
random allocation
randomised
randomised controlled trial
randomization
Randomized controlled trial
Rapid
recruited
red blood cell
renal replacement therapy
replacement therapy
response
responsible
reverse transcriptase
Reverse transcriptase polymerase chain reaction
risk
risk difference
rivaroxaban
room air
Sample size
Saudi Arabia
secondary
Secondary outcomes
Standard
standard care
status
stratified
study population
Study protocol
supplementary material
symptomatic
the patient
the United State
therapeutic anticoagulation
therapeutic dose
therapy
thrombocytopenia
Thromboembolism
Thromboprophylaxis
tinzaparin
transcriptase
transfusion
treated
Trial
Trial registration
two-sided
ULN
unfractionated heparin
United Arab Emirates
United States
Venous Thromboembolism
Ventilator-free days
Version
Warfarin
website
World Health Organization
[DOI] 10.1186/s13063-021-05076-0 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-021-05076-0 PMC 바로가기 [Article Type] Letter